Microtubule dynamics as a target in oncology

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors for decades. New, more effective microtubule-targeting agents continue to enter into clinical trials and some, including the epothilone ixapebilone, have been approved for use. In contrast, several other drugs of this class with promising preclinical data were later shown to be ineffective or intolerable in animal models or clinical trials. In this review, we discuss the molecular mechanisms as well as preclinical and clinical results for a variety of microtubule-targeting agents in various stages of development. We also offer a frank discussion of which microtubule-targeting agents are amenable to further development based on their availability, efficacy and toxic profile.

Original languageEnglish (US)
Pages (from-to)255-261
Number of pages7
JournalCancer Treatment Reviews
Volume35
Issue number3
DOIs
StatePublished - May 2009

Fingerprint

Microtubules
Epothilones
Clinical Trials
Vinca Alkaloids
Taxoids
Poisons
Pharmaceutical Preparations
Leukemia
Animal Models
Neoplasms

Keywords

  • 2-Methoxyestradiol
  • Colchicine
  • Discodermolide
  • Epothilone
  • Halichondrin B
  • Microtubule
  • Microtubule-targeting agent
  • Taccalonolide
  • Taxane
  • Vinca alkaloid

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Microtubule dynamics as a target in oncology. / Risinger, April L; Giles, Francis J.; Mooberry, Susan L.

In: Cancer Treatment Reviews, Vol. 35, No. 3, 05.2009, p. 255-261.

Research output: Contribution to journalArticle

@article{23f66e2cfe41456badc449424043b5e3,
title = "Microtubule dynamics as a target in oncology",
abstract = "Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors for decades. New, more effective microtubule-targeting agents continue to enter into clinical trials and some, including the epothilone ixapebilone, have been approved for use. In contrast, several other drugs of this class with promising preclinical data were later shown to be ineffective or intolerable in animal models or clinical trials. In this review, we discuss the molecular mechanisms as well as preclinical and clinical results for a variety of microtubule-targeting agents in various stages of development. We also offer a frank discussion of which microtubule-targeting agents are amenable to further development based on their availability, efficacy and toxic profile.",
keywords = "2-Methoxyestradiol, Colchicine, Discodermolide, Epothilone, Halichondrin B, Microtubule, Microtubule-targeting agent, Taccalonolide, Taxane, Vinca alkaloid",
author = "Risinger, {April L} and Giles, {Francis J.} and Mooberry, {Susan L}",
year = "2009",
month = "5",
doi = "10.1016/j.ctrv.2008.11.001",
language = "English (US)",
volume = "35",
pages = "255--261",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Microtubule dynamics as a target in oncology

AU - Risinger, April L

AU - Giles, Francis J.

AU - Mooberry, Susan L

PY - 2009/5

Y1 - 2009/5

N2 - Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors for decades. New, more effective microtubule-targeting agents continue to enter into clinical trials and some, including the epothilone ixapebilone, have been approved for use. In contrast, several other drugs of this class with promising preclinical data were later shown to be ineffective or intolerable in animal models or clinical trials. In this review, we discuss the molecular mechanisms as well as preclinical and clinical results for a variety of microtubule-targeting agents in various stages of development. We also offer a frank discussion of which microtubule-targeting agents are amenable to further development based on their availability, efficacy and toxic profile.

AB - Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors for decades. New, more effective microtubule-targeting agents continue to enter into clinical trials and some, including the epothilone ixapebilone, have been approved for use. In contrast, several other drugs of this class with promising preclinical data were later shown to be ineffective or intolerable in animal models or clinical trials. In this review, we discuss the molecular mechanisms as well as preclinical and clinical results for a variety of microtubule-targeting agents in various stages of development. We also offer a frank discussion of which microtubule-targeting agents are amenable to further development based on their availability, efficacy and toxic profile.

KW - 2-Methoxyestradiol

KW - Colchicine

KW - Discodermolide

KW - Epothilone

KW - Halichondrin B

KW - Microtubule

KW - Microtubule-targeting agent

KW - Taccalonolide

KW - Taxane

KW - Vinca alkaloid

UR - http://www.scopus.com/inward/record.url?scp=64049097460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64049097460&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2008.11.001

DO - 10.1016/j.ctrv.2008.11.001

M3 - Article

C2 - 19117686

AN - SCOPUS:64049097460

VL - 35

SP - 255

EP - 261

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 3

ER -